Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …

Overview I n 2010, approximately 12,330 people were diagnosed with and 8950 died of
acute myeloid leukemia (AML). 1 As the population ages, the incidence of AML, along with …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …

Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Evidence suggest that even patients aged 70 or above benefit from specific AML therapy.
The fundamental decision in AML then becomes whether to recommend standard or …

The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of high-
risk patients with multiple and varied poor prognostic features. These neoplasms are thought …

Acute myeloid leukemia (AML) is primarily a disease of older adults. Many older patients
with AML are not candidates for intensive chemotherapy regimens aimed at inducing …

High-risk acute myelogenous leukemia (AML) constitutes a distinct subset of disease based
on clinical and biological characteristics and comprises a significant percentage of all cases …